Dossier assessment
Canagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Canagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
-
Dossier assessment
Canagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Press releases
Type 2 diabetes mellitus: Added benefit of canagliflozin is not proven
Drug manufacturer’s dossier did not provide suitable data for any therapeutic indication
Additional information
Federal Joint Committee (G-BA)
2014-09-04 A G-BA decision was published.
Project details
- Project no.
- A14-12
- Commission
- Commission awarded on 14.03.2014 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.